The Annual Process Development for Cell Therapies Summit- What's It About?
The annual Process Development For Cell Therapies Summit 2025 streamlined cell therapy development and manufacturing processes, uniting experts across process development, technical operations, QC, AD, CMC, MSAT, and beyond. Our mission was driving the production of safe, effective, and consistent autologous and allogeneic cell therapies.
What Was New for 2025?
In response to industry feedback, this year's summit featured specialized workshops tailored to both early and late-stage process development challenges. Gaining targeted insights to optimize scalability, reproducibility, and product quality.
We explored the latest automation solutions—from qualification to drug product application—to enhance efficiency and reduce variability.
Don’t miss the chance to engage with the brightest minds in cell therapy in 2026.
2025 Attendees Saw:
Accelerate scale-up and commercialization of cell therapies by optimizing process development, navigating regulatory challenges, and collaborating effectively with CDMOs to ensure consistent quality and efficient tech transfer with Tenpoint Therapeutics, Johnson & Johnson, Arsenal Bio & BMS
Enhance product consistency and quality with optimized CQAs and control strategies alongside Cabaletta Bio, Immatics, Genetech, Cellectis & more by employing high-throughput analytics, streamlining raw material management, optimizing cryopreservation profiles and addressing donor variability across autologous and allogeneic therapies
Leverage automation, AI, and advanced analytics to drive manufacturing efficiency by integrating real-time data collection, automating workflows, and improving predictive insights to reduce costs and accelerate production timelines with Galapagos, Artiva Biotherapeutics, Lyell Pharma & Takeda
Ensure process comparability and regulatory alignment by establishing robust early-stage foundations, and hear from Immatics, Takeda, and BioNTech on managing process changes in late-stage development, and balancing standardization with customization across diverse indications.
Attendees Met:
Industry leaders, decision-makers, technical experts, and leading solution providers committed to advancing the PD space. This diverse group included innovators shaping both early and late-stage process development, automation solutions, and the manufacturing of autologous and allogeneic cell therapies.
If you’d like more details on the 2025 summit’s audience breakdown and companies in the room, feel free to schedule an event consultation with the team here.
What Your Peers Had to Say:
“The niche focus made all the talks highly relevant, and the speakers were excellent.”
– 2025 Speaker, Associate Director, Inceptor Bio
“The narrow scope and intimate setting made it easy to have meaningful conversations with everyone.”
– 2024 Attendee, Scientist, Vor Bio
“The intimate nature of the meeting created an environment where conversations flowed naturally. The talks were high-quality and focused, adding real value.”
– 2024 Attendee, Senior Director, Neogene Therapeutics